Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

VNDA

Live52w high -36.8%

Annual Quarterly

Core line items from VNDA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Annual Quarterly

Entity: VANDA PHARMACEUTICALS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-07-29	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$62.81M	$51.72M	$216.10M	$158.89M	$102.63M
Operating Income	Not available	$-50.22M	$-151.17M	$-110.81M	$-79.53M
Net Income	Not available	$-48.57M	$-220.47M	$-79.29M	$-27.21M
EPS (Diluted)	$-0.62	$-0.82	$-3.74	$-1.35	$-0.96
Total Assets	Not available	$433.52M	$488.95M	$601.14M	$624.75M
Total Liabilities	Not available	$152.76M	$161.76M	$135.14M	$138.42M
Cash & Equivalents	Not available	$54.03M	$84.85M	$70.02M	$80.98M
Free Cash Flow OCF − CapEx	Not available	$-50.44M	$-110.44M	$-80.92M	$-49.13M
Shares Outstanding	Not available	60.14M	59.10M	59.10M	59.08M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.

Core line items from VNDA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -36.8%

Entity: VANDA PHARMACEUTICALS INC.·Source: SEC EDGAR companyfacts·Next-Q consensus from Finnhub

Metric	Q3 2026 (Est.) Expected 2026-07-29	Q1 2026 2026-03-31	Annual 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30
Revenue	$62.81M	$51.72M	$216.10M	$158.89M	$102.63M
Operating Income	Not available	$-50.22M	$-151.17M	$-110.81M	$-79.53M
Net Income	Not available	$-48.57M	$-220.47M	$-79.29M	$-27.21M
EPS (Diluted)	$-0.62	$-0.82	$-3.74	$-1.35	$-0.96
Total Assets	Not available	$433.52M	$488.95M	$601.14M	$624.75M
Total Liabilities	Not available	$152.76M	$161.76M	$135.14M	$138.42M
Cash & Equivalents	Not available	$54.03M	$84.85M	$70.02M	$80.98M
Free Cash Flow OCF − CapEx	Not available	$-50.44M	$-110.44M	$-80.92M	$-49.13M
Shares Outstanding	Not available	60.14M	59.10M	59.10M	59.08M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data. The amber (Est.) column shows Wall Street analyst consensus for the next reporting period — only Revenue and EPS are covered by published consensus, so other line items remain blank. These are third-party estimates, not company guidance.